A stepwise dose increase of febuxostat was comparable to prophylactic low-dose colchicine for reducing flares in an open-label, randomized study of 241 patients with gout. Flares occurred in 20.8% of patients taking stepped-up (10 mg to 40 mg daily) febuxostat and in 18.9% of patients taking 40 mg daily febuxostat with low-dose colchicine, incidences that were significantly lower than those seen in patients taking 40 mg daily febuxostat alone (P = 0.047 and P = 0.024, respectively).
References
Yamanaka, H. et al. Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2017-211574 (2017)
Rights and permissions
About this article
Cite this article
Collison, J. Stepping up febuxostat to treat gout flares. Nat Rev Rheumatol 14, 4 (2018). https://doi.org/10.1038/nrrheum.2017.193
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2017.193